Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 11/20 | 1.00 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.63 |
| ▸ | HTR7 | P34969 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.55 |
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21465236 | 1.00 | MAPKAPK2 (1.00) | MAPKAPK2MAPKAPK5HTR7CYP3A4CYP2D6 | |
| SCHEMBL12395388 | 1.00 | MAPKAPK2 (1.00) | MAPKAPK2MAPKAPK5HTR7CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL10406908 | 0.99 | MAPKAPK2 (0.97) | MAPKAPK2MAPKAPK5HTR7CYP3A4CYP2D6 | |
| SCHEMBL28439443 | 0.87 | MAPKAPK2 (0.77) | MAPKAPK2MAPKAPK5HTR7CYP3A4CYP2D6 | |
| SCHEMBL9696707 | 0.87 | MAPKAPK2 (0.77) | MAPKAPK2MAPKAPK5HTR7CYP3A4CYP2D6 | |
| SCHEMBL29264061 | 0.84 | MAPKAPK2 (0.72) | MAPKAPK2MAPKAPK5HTR7CYP3A4CYP2D6 | |
| SCHEMBL28918986 | 0.83 | MAPKAPK2 (0.71) | MAPKAPK2HTR7CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL1491406 | 0.83 | MAPKAPK2 (0.71) | MAPKAPK2MAPKAPK5HTR7CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL28201946 | 0.82 | MAPKAPK2 (0.70) | MAPKAPK2MAPKAPK5HTR7CYP3A4CYP2D6 | |
| SCHEMBL19412092 | 0.82 | MAPKAPK2 (0.69) | MAPKAPK2MAPKAPK5HTR7CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10751330-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-25 | — | — | US | claimed |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-05-14 | — | — | US | claimed |
| CN-109456319-A | A kind of preparation and purposes of CDK4 inhibitor | 兰州大学 | 2019-03-12 | — | — | CN | claimed |
| US-10092550-B2 | Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof | IONS PHARMACEUTICAL S.À R.L. (LU) | 2018-10-09 | — | — | US | claimed |
| US-20170105975-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-04-20 | — | — | US | claimed |
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-02-16 | — | — | US | claimed |
| US-12592370-B2 | Screening with mass spectrometry for mycobacteria prior to cardiothoracic surgery | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2026-03-31 | — | — | US | disclosed |
| US-12545944-B2 | Method of detection | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2026-02-10 | — | — | US | disclosed |
| US-20240390294-A1 | INHIBITION OF COVID-19 VIRUS BY MULTIPLE-COMPONENT FORMULATIONS | ANKH LIFE SCIENCES LIMITED (IE) | 2024-11-28 | — | — | US | disclosed |
| US-20240285592-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2024-08-29 | — | — | US | disclosed |
| US-12053440-B2 | Inhibition of COVID-19 virus by formulations containing curcumin, harmine, and isovanillin | ANKH LIFE SCIENCES LIMITED (IE) | 2024-08-06 | — | — | US | disclosed |
| US-11951099-B2 | Methods for treating plasma cell neoplasm with human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2024-04-09 | — | — | US | disclosed |
| US-20230135821-A1 | SCREENING WITH MASS SPECTROMETRY FOR MYCOBACTERIA PRIOR TO CARDIOTHORACIC SURGERY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-05-04 | — | — | US | disclosed |
| US-5554756-A | PROTEASE INHIBITOR | HOFFMANN-LA ROCHE INC. (US) | 1996-09-10 | — | — | US | disclosed |
| US-5446161-A | Protease inhibitor, viricides | HOFFMANN-LA ROCHE INC. (US) | 1995-08-29 | — | — | US | disclosed |
| EP-0346847-B1 | Amino acid derivatives | HOFFMANN LA ROCHE (CH) | 1994-05-11 | — | — | EP | disclosed |
| US-5157041-A | Viricides | HOFFMANN-LA ROCHE INC. (US) | 1992-10-20 | — | — | US | disclosed |
| US-4978669-A | ALTERING MACRONUTRIENT PREFERENCE | NEUREX CORPORATION (US) | 1990-12-18 | — | — | US | disclosed |
| WO-1990003168-A1 | METHOD FOR MODIFYING FEEDING BEHAVIOR | NEUREX CORPORATION (US) | 1990-04-05 | — | — | WO | disclosed |
| EP-0346847-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11951099-B2 | Methods for treating plasma cell neoplasm with human therapeutic agents | MCL1, CD44, INMT | MAPKAPK2 3991/4885MAPKAPK5 3741/4885HTR7 904/4885 |
| US-10751330-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | MAPKAPK2 3624/4885MAPKAPK5 3577/4885HTR7 76/4885 |
| US-20240285592-A1 | HUMAN THERAPEUTIC AGENTS | INMT, NLN, MYC | MAPKAPK2 3175/4885MAPKAPK5 3524/4885HTR7 125/4885 |
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, CPT1A | MAPKAPK2 3520/4885MAPKAPK5 3279/4885HTR7 96/4885 |
| US-12592370-B2 | Screening with mass spectrometry for mycobacteria prior to cardiothoracic surgery | FABP3, ACADM, TST | MAPKAPK2 3363/4885MAPKAPK5 1820/4885HTR7 3620/4885 |
| US-12545944-B2 | Method of detection | PHOSPHO1, NAAA, LIPA | MAPKAPK2 2731/4885MAPKAPK5 1821/4885HTR7 2096/4885 |
| US-10092550-B2 | Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof | INMT, HNMT, CPT1A | MAPKAPK2 3520/4885MAPKAPK5 3279/4885HTR7 96/4885 |
| US-12053440-B2 | Inhibition of COVID-19 virus by formulations containing curcumin, harmine, and isovanillin | MAVS, IDO2, IDO1 | MAPKAPK2 2897/4885MAPKAPK5 3678/4885HTR7 121/4885 |
| US-20170105975-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | MAPKAPK2 3472/4885MAPKAPK5 3040/4885HTR7 29/4885 |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | MAPKAPK2 3624/4885MAPKAPK5 3577/4885HTR7 76/4885 |
| US-20240390294-A1 | INHIBITION OF COVID-19 VIRUS BY MULTIPLE-COMPONENT FORMULATIONS | MAVS, IDO2, IDO1 | MAPKAPK2 2904/4885MAPKAPK5 3469/4885HTR7 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.